- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00758082
Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients (TELFIT)
Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study
TELFIT is a monocenter, controlled, randomised trial. It focuses on type 1 diabetes patients that have attended a functional insulin therapy training course. The Primary objective of the TELFIT study is to evaluate whether a PDA with telemonitoring by phone reinforces the effects of the functional insulin therapy training course as compared with conventional care.
Main judgment criteria: comparison of HbA1c means between M0 (start) and M3(3 months)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Grenoble, Frankreich, 38043
- University Hospital Grenoble
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Type 1 diabetes mellitus for ≥ 6 months or more
- Age > 18 year old
- The patient has attended a functional insulin therapy class or workshop
- Insulin basal-bolus therapy for at least 6 months. At inclusion, patients should be treated either with a long-acting insulin and insulin rapid analog before each meal, or with rapid insulin analog delivered with a pump
- Ability to understand how the PDA-phone works and ability to use it
- Social Security membership or benefit from Social Security
- Patients equipped with a memory blood glucose monitor
- Informed consent, with a signed and approved form
Exclusion Criteria:
- Underage patient, major patient under guardianship or protected by the Law
- Patient with any unstable associated evolutive pathology that could cause a diabetes imbalance within the coming year
- Change in diabetes treatment within the 3 months before inclusion or planned during the study
- Patient who needs a more frequent diabetic follow-up than in the protocol (especially severe or evolving complication due to diabetes)
- Patient attending another education program within the 3 months before inclusion or planning to attend one during the study
- Patient with toxicomania, alcoholism or psychological troubles that could impact the study
- Type-2-diabetic patient
- Patient who doesn't need strict metabolic objectives
- Pregnant or possibly pregnant woman
- Person with no freedom (prisoner)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: 1
Patients will have face to face visits at 3 months and no PDA-phone.
Patients will record glycemia on paper support
|
Patients will have face to face visits at 3 months and no PDA-phone.
Patients will record glycemia on paper support.
|
|
Experimental: 2
PDA-phone + phone consultations + standard visit at 3 months
|
Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Comparison of HbA1c means
Zeitfenster: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Difference between theoretical insulin dose and actual dose, one week before the 3-month reevaluation session
Zeitfenster: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
|
DHP scale of quality of life and satisfaction dimension of the DQOL questionnaire
Zeitfenster: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
|
Time spent by physicians and nurses in the different groups
Zeitfenster: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
|
Weight changes during the 3-month period
Zeitfenster: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
|
Number of hypoglycemias (moderate and severe) during the 3-month period
Zeitfenster: M0 (start) and M3 (3 months)
|
M0 (start) and M3 (3 months)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Pierre Y Benhamou, PhD, University Hospital, Grenoble
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2008-A00389-46
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .